» Articles » PMID: 20037776

FGF2-adsorbed Macroporous Hydroxyapatite Bone Granules Stimulate in Vitro Osteoblastic Gene Expression and Differentiation

Overview
Publisher Springer
Date 2009 Dec 29
PMID 20037776
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Hydroxyapatite bone granules with a macroporous structure were produced and then adsorbed with basic fibroblast growth factor (FGF2). The in vitro scaffolding role of the granules in cell population and osteogenic differentiation was investigated. The FGF2-adsorbed porous granules allowed the MC3T3-E1 cells to adhere well and then proliferate actively. While the cell growth level on the FGF2-treated granules was observed to be similar to that on the untreated granules, the expression of genes associated with bone, including collagen type I, alkaline phosphatase, and osteocalcin was significantly upregulated by the FGF2 treatment, particularly at the early stage. Moreover, the production of alkaline phosphatase with prolonged culturing was greatly enhanced on the FGF2-adsorbed granules. Taken together, the FGF2 treatment of the hydroxyapatite granules was effective in the osteogenic development and the FGF2-adsorbed bone granules may be useful in bone regeneration area.

Citing Articles

Synthesis of nano-hydroxyapatite using emulsion, pyrolysis, combustion, and sonochemical methods and biogenic sources: a review.

Alam M, Hossain M, Kawsar M, Bahadur N, Ahmed S RSC Adv. 2024; 14(5):3548-3559.

PMID: 38259993 PMC: 10801447. DOI: 10.1039/d3ra07559a.


Mechanistic Illustration: How Newly-Formed Blood Vessels Stopped by the Mineral Blocks of Bone Substitutes Can Be Avoided by Using Innovative Combined Therapeutics.

Bornert F, Clauss F, Hua G, Idoux-Gillet Y, Keller L, Fernandez De Grado G Biomedicines. 2021; 9(8).

PMID: 34440156 PMC: 8394928. DOI: 10.3390/biomedicines9080952.


Potential of Soluble Decellularized Extracellular Matrix for Musculoskeletal Tissue Engineering - Comparison of Various Mesenchymal Tissues.

Hanai H, Jacob G, Nakagawa S, Tuan R, Nakamura N, Shimomura K Front Cell Dev Biol. 2020; 8:581972.

PMID: 33330460 PMC: 7732506. DOI: 10.3389/fcell.2020.581972.


Fibroblast Growth Factor 2-A Review of Stabilisation Approaches for Clinical Applications.

Benington L, Rajan G, Locher C, Lim L Pharmaceutics. 2020; 12(6).

PMID: 32498439 PMC: 7356611. DOI: 10.3390/pharmaceutics12060508.


Enhanced osteoinductive capacity and decreased variability by enrichment of demineralized bone matrix with a bone protein extract.

Ramis J, Calvo J, Matas A, Corbillo C, Gaya A, Monjo M J Mater Sci Mater Med. 2018; 29(7):103.

PMID: 29956013 DOI: 10.1007/s10856-018-6115-8.


References
1.
Rouwkema J, Rivron N, van Blitterswijk C . Vascularization in tissue engineering. Trends Biotechnol. 2008; 26(8):434-41. DOI: 10.1016/j.tibtech.2008.04.009. View

2.
Mackie E, Trechsel U . Stimulation of bone formation in vivo by transforming growth factor-beta: remodeling of woven bone and lack of inhibition by indomethacin. Bone. 1990; 11(4):295-300. DOI: 10.1016/8756-3282(90)90083-b. View

3.
Behairy Y, Jasty M . Bone grafts and bone substitutes in hip and knee surgery. Orthop Clin North Am. 1999; 30(4):661-71. DOI: 10.1016/s0030-5898(05)70118-8. View

4.
Meyers G, Orlow S, Munro I, Przylepa K, Jabs E . Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet. 1995; 11(4):462-4. DOI: 10.1038/ng1295-462. View

5.
Mistry A, Mikos A . Tissue engineering strategies for bone regeneration. Adv Biochem Eng Biotechnol. 2005; 94:1-22. DOI: 10.1007/b99997. View